| abstract |
This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, this invention provides also a method of treating a disease that responds to the inhibition of MMP-13 and cyclooxygenase-2, which comprises administering to a patient suffering from such a disease the combination of the invention comprising an allosteric carboxylic MMP-13 inhibitor, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof; This invention also provides a pharmaceutical composition, comprising the combination of the invention comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient; The combination of the invention can also be combined additionally with other pharmaceutical agents depending on the disease to be treated. |